Vident Advisory’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Vident Advisory’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,586	Closed	-$209K	–	1720
2025 Q1	$209K	Buy	+1,586	New	+$198K	﹤0.01%	1431
2024 Q2	–	Sell	-3,772	Closed	-$261K	–	1525
2024 Q1	$261K	Buy	3,772 +582	+18%	+$40K	0.01%	1098
2023 Q4	$228K	Buy	+3,190	New	+$184K	0.01%	1149

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Vident Advisory's ITCI Position: Q2 2025 in Review

Vident Advisory sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,586 shares — an estimated $209K sold.

Vident Advisory first reported a position in ITCI in Q4 2023 and held it in 3 quarters. The position peaked at $261K in Q1 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Vident Advisory reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Vident Advisory sold 1,586 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $209K.
Vident Advisory first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 3 quarters.
Vident Advisory's Intra-Cellular Therapies Inc. position peaked at $261K in Q1 2024.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Vident Advisory's 13F filing for Q2 2025, filed 14 Aug 2025.